Earth is divided into two halves: the Northern and Southern Hemispheres. Both reflect equal amounts of sunlight (albedo) even ...

A new study suggests Antarctica’s ice sheet hit a climate tipping point about one million years ago, making it far more reactive to temperature and CO2 changes. Researchers warn this surprising ...

If you haven’t heard the Gen Z term “weekend-maxxing” before, trust us when we say it’s a trend you’ll actually want to get on board with. The concept is simple: Instead of treating a Friday-to-Sunday ...

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Public opposition to data centers is hardening as overwhelming majorities of Americans now oppose construction of the facilities in their communities, according to a newly released Gallup survey. The ...

Developers of the proposed data center along W.Va. 62 north of Point Pleasant, West Virginia, have submitted their application for a construction permit to the West Virginia Department of ...

As global temperatures rise, data centers for artificial intelligence are creating “heat islands” that could have significant impacts on communities and their surrounding environments in the years to ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...